decisionhealth Newsletters, Coder Pink Sheets - 2005 Issue 12 (December)
Looming costs for bladder cancer meds force ASP/CAP decisions
Subscribe or sign in to view the full article.
Article Overview
This article examines how urology practices are weighing drug reimbursement and purchasing options in light of rising costs and changing Medicare payment approaches. It focuses on operational and financial considerations for office-administered therapies, practice workflow, and where patients may receive treatment, making it relevant to urologists, practice administrators, and billing/coding professionals who work with Medicare Part B drug services.
Why This Topic Matters
The piece highlights how payment methodology can affect practice finances, staffing, and site-of-care decisions for commonly used urology drugs. It is useful for understanding the broader reimbursement environment affecting office-based administration and related administrative planning.
What You Will Learn
- How Medicare drug reimbursement approaches affect urology practice finances
- What operational issues practices consider when choosing a purchasing and billing model
- Why staffing, scheduling, and site-of-care decisions matter for office-administered therapies
- How practice size and drug acquisition arrangements can influence reimbursement outcomes
Who Should Read This
- Urologists
- Practice administrators
- Medical billing and coding professionals
- Healthcare finance staff
- Revenue cycle teams
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com